Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular Therapies

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Breast cancer subtypes exhibit unique biology influencing therapeutic response.
• Immunotherapy, especially immune checkpoint inhibitors (ICIs), has shown success in triple-negative breast cancer (TNBC).
• Resistance to ICIs is common due to low tumor immunogenicity and immunosuppressive microenvironments.

Purpose of the Study:

• To review current clinical evidence for immunotherapies in breast cancer.
• To highlight emerging cellular immunotherapy strategies.
• To discuss challenges and future directions in breast cancer immunotherapy.

Main Methods:

• Review of current clinical evidence for immunotherapies in breast cancer.
• Summary of emerging cellular immunotherapy strategies (CAR T-cell, TIL, TCR, CAR-NK).
• Discussion of key challenges: antigen specificity, toxicity, and resistance.

Main Results:

• ICIs combined with chemotherapy are a standard of care for TNBC in early and metastatic settings.
• Cellular immunotherapies targeting antigens like HER2, ROR1, MUC1, mesothelin, and B7-H3 are in early clinical evaluation.
• Various cellular approaches aim to overcome antigen presentation barriers and immune evasion.

Conclusions:

• Cellular immunotherapy represents a potential next frontier for breast cancer treatment.
• Overcoming resistance requires addressing antigen specificity, off-tumor toxicity, and the tumor microenvironment.
• Future progress depends on combination approaches and next-generation engineered immune cells for durable, personalized benefit.